A greater efficacy in treatment of chronic hepatitis C was observed in combination with IFN-α and ribavirin[24], which has been available in Taiwan since August 1998 and becomes to be the recommendations for chronic hepatitis C patients[18,19]. This evidence concerns the gene IFNA2 and chronic hepatitis C virus infection.